Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
have emerged as the mainstay of treatment for advanced EGFR-mutant advanced non-small …

Recently, targeted therapy and immunotherapy have emerged as effective treatment options
for non-small cell lung cancer (NSCLC). This progress has been facilitated by the rapid …

Over the past decade, immunotherapy delivered novel treatments for many cancer types.
However, lung cancer still leads cancer mortality, and non-small-cell lung carcinoma …

Oncogenic mutations in the EGFR gene are targets of tyrosine kinase inhibitors (TKIs) in
lung adenocarcinoma (LC) patients, and their search is mandatory to make decisions on …

Introduction Treatment landscape for advanced/metastatic NSCLC (aNSCLC) has evolved
considerably over the past few decades with the advent of targeted therapies for epidermal …

Tryptophan catabolism plays an important role in the metabolic reconnection in cancer cells
to support special demands of tumor initiation and progression. The catabolic product of the …

Lung cancer is one of the most common malignant tumors with high mortality rate. Hungary
was reported to have one of the highest incidence and mortality rates of lung cancer …

Purpose Epidermal growth factor receptor (EGFR) T790M-negative/unknown advanced non-
small cell lung cancer (NSCLC) patients lack subsequent approved targeted therapies. This …

Background and Objectives: Epidermal growth factor receptor–tyrosine kinase inhibitors
(EGFR-TKIs) are effective first-line chemotherapeutic agents for patients with advanced non …

Lung cancer remains the leading cause of cancer death in the United States, underscoring
the critical need to optimize treatment strategies. Compared to conventional treatments such …